Akebia Therapeutics Reports Inducement Grants

Biopharmaceutical company grants stock options to new hires under Nasdaq rule

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, has granted stock options to five newly hired employees. The options, granted in accordance with Nasdaq Listing Rule 5635(c)(4), allow the employees to purchase a total of 46,200 shares of Akebia's common stock at an exercise price of $1.31 per share.

Why it matters

Inducement grants like these are common practice for public companies to attract and retain talent, especially in the competitive biopharmaceutical industry. The grants align the new employees' interests with those of Akebia's shareholders by providing them a stake in the company's future performance.

The details

The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is subject to the terms of Akebia's inducement award program.

The options were granted on February 27, 2026.

The players